Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Baxter International (NYSE:BAX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.
Analyst Recommendations
This is a breakdown of recent ratings for Anteris Technologies Global and Baxter International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| Baxter International | 2 | 9 | 2 | 0 | 2.00 |
Anteris Technologies Global currently has a consensus target price of $16.00, indicating a potential upside of 106.72%. Baxter International has a consensus target price of $22.45, indicating a potential downside of 4.48%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than Baxter International.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
| Baxter International | -9.27% | 16.57% | 5.24% |
Volatility & Risk
Anteris Technologies Global has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Insider and Institutional Ownership
90.2% of Baxter International shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Anteris Technologies Global and Baxter International”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $2.24 million | 336.45 | -$94.14 million | ($1.95) | -3.97 |
| Baxter International | $11.24 billion | 1.08 | -$957.00 million | ($2.07) | -11.36 |
Anteris Technologies Global has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Summary
Anteris Technologies Global beats Baxter International on 9 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
